Skip to main content

Table 2 Demographics

From: Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis

Study, Year

Age PCC3

Age PCC4

Male PCC3 (%)

Male PCC4 (%)

Weight PCC3 (kg)

Weight PCC4 (kg)

Al-Majzoub et al., 2016 [20]

79 [70–87]

82 [76–88]

19 (54.3%)

10 (55.5%)

81.3 (15.0)

74.5 (12.7)

DeAngelo et al., 2018 [22]

68.9 (14.2)

70.0 (13.7)

38 (66.7%)

14 (40.6%)

89.3 (24.9)

80.8 (29.1)

Fischer et al., 2018 [24]

77 [73–82]

80 [73–86]

17 (42.5%)

34 (54%)

NR

NR

Holt et al., 2018 [25]

74 (10.8)

57 (14.7)

43 (55.8%)

29 (50.9%)

87.9 (26.9)

84.9 (22.6)

Jones et al., 2016 [27]

75.5 [64.0–83.0]

72.5 [58.5–80.0]

45 (53.6%)

38 (59.4%)

84.8 [70.2–100.8]

82.5 [72.4–100.3]

Kuroski et al., 2017 [28]

74.5 (NR)

76.2 (NR)

36 (53.0%)

37 (53.6%)

78.7 (NR)

85.7 (NR)

Mangram et al., 2016 [30]

76 (13)

77 (8)

25 (54.3%)

10 (55.5%)

80 (22)

83 (18)

Margraf et al., 2020 [31]

74.0 [62.0–80.0]

66.0 [57.0–82.0]

36 (63.2%)

12 (52.2%)

81.4 [72.1–94.4]

77.8 [64.7–97.8]

Mohan et al., 2018 [32]

73.54 (28–102, 76.50) Mean (range, median) (both groups)

73.54 (28–102, 76.50) Mean (range, median) (both groups)

83 (65%) (both groups)

83 (65%) (both groups)

77.9 (NR) (both groups)

77.9 (NR) (both groups)

Voils et al., 2015 [33]

71.8 (13.1)

70.4 (13.4)

31 (55%)

64 (55%)

85 (25)

88 (23)

Cang et al., 2014 [21]

NR

NR

NR

NR

NR

NR

Di Napoli et al., 2014 [23]

NR

NR

NR

NR

NR

NR

Kotsianas et al., 2015 [26]

NR

NR

NR

NR

NR

NR

Peck et al., 2016 [29]

NR

NR

NR

NR

NR

NR

Wagner et al., 2019 [34]

68 [59, 80] (both groups)

68 [59, 80] (both groups)

NR

NR

NR

NR

  1. Age and weight reported as mean (SD), median [IQR], or mean (min-max, median)
  2. PCC prothrombin complex concentrate, PCC3 3 factor PCC, PCC4 4 factor PCC